Investors & Media

Investors & Media

Corporate Profile

At Travere Therapeutics, our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.

Volume: 52 Week High: 52 Week Low:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Oct 14, 2021
Travere Therapeutics to Report Third Quarter 2021 Financial Results
SAN DIEGO , Oct. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2021 financial results on Thursday, October 28, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET .
Oct 13, 2021
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 74,900 shares of its common stock to eleven new employees, consisting of inducement stock options to purchase an aggregate of 62,100 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 12,800 shares of its common stock.
Oct 12, 2021
Travere Therapeutics Announces Transition of Chief Medical Officer
SAN DIEGO , Oct. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief medical officer, Noah Rosenberg , M.D., has chosen to transition for personal reasons to an executive advisor role at the end of 2021.

Events & Presentations